N-Trimethyl chitosan-coated multivesicular liposomes for oxymatrine oral delivery

Drug Development and Industrial Pharmacy

Volumn 35, Issue 11, 2009, Pages 1339-1347

  Cao, Jinna ^a   Sun, Jukui ^a   Wang, Xiaoyu ^a   Li, Xinran ^a   Deng, Yingjie ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Multivesicular liposome; N trimethyl chitosan; Oral delivery; Oxymatrine; Surface coating

Indexed keywords

CHITOSAN DERIVATIVE; LIPOSOME; MATRINE; MULTIVESICULAR LIPOSOME; N TRIMETHYLCHITOSAN CHLORIDE; OXYMATRINE; UNCLASSIFIED DRUG; WATER OIL CREAM;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG STABILITY; DRUG SYNTHESIS; ENCAPSULATION; FEMALE; INTESTINE FLUID; LIPID VESICLE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; RAT; SINGLE DRUG DOSE; STOMACH JUICE; STOMACH PH; SURFACE PROPERTY; TIME TO MAXIMUM PLASMA CONCENTRATION; ZETA POTENTIAL;

ADMINISTRATION, ORAL; ALKALOIDS; ANIMALS; ANTIVIRAL AGENTS; CHITOSAN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG COMPOUNDING; DRUG STABILITY; FEMALE; GASTRIC JUICE; HEPATITIS B; HYDROGEN-ION CONCENTRATION; INTESTINAL SECRETIONS; LIPOSOMES; MODELS, BIOLOGICAL; QUINOLIZINES; RATS; RATS, WISTAR;

EID: 70350344325     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040902902427     Document Type: Article

References (24)

1. Lu LG, Zeng MD, Mao YM, Li JQ, Wan MB, Li CZ, et al. (2003). Oxymatrine therapy for chronic hepatitis B: A randomized doubleblind and placebo-controlled multicenter trial. World J Gastroenterol, 9:2480-2483
2. Du S, Deng YJ, Liang W. (2006). Physicochemical properties study of oxymatrine. J Shenyang Pharmaceutical University, 23:80-83
3. Li ZW, Ma XY, Wang MN, Liang WW, Wang YH. (2004). Investigation of pharmacokinetics of oxymatrine soft capsule in healthy volunteers. Northwest Pharm J, 19(4):149-151
4. Ellena JF, Le M, Cafiso D, Solis RM, Langston M, Sankaram MB. (1999). Distribution of phospholipids and triglycerides in multivesicular lipid particles. Drug Deliv, 6:97-106.
5. Mantripragada S. (2002). A lipid based depot (DepoFoam technology) for sustained release drug delivery. Prog Lipid Res, 41:392-406.
6. Grayson LS, Hansbrough JF, Zapata-Sirvent RL, Kim T, Kim S. (1993). Pharmacokinetics of DepoFoam gentamicin delivery system and effect on soft tissue infection. J Surg Res, 55:559-564
7. Huh J, Chen JC, Furman GM, Malki C, King B, Kafie F, et al. (1998). Local treatment of prosthetic vascular graft infection with multivesicular liposome-encapsulated amikacin. J Surg Res, 74:54-58
8. Jain SK, Jain RK, Chourasia MK, Jain AK, Chalasani KB, Soni V, et al. (2005). Design and development of multivesicular liposomal depot delivery system for controlled systemic delivery of acyclovir sodium. AAPS PharmSciTech, 6:E35-41.
9. Langston MV, Ramprasad MP, Kararli TT, Galluppi GR, Katre NV. (2003). Modulation of the sustained delivery of myelopoietin (Leridistim) encapsulated in multivesicular liposomes (DepoFoam). J Control Release, 89:87-99.
10. Ramprasad MP, Amini A, Kararli T, Katre NV. (2003). The sustained granulopoietic effect of progenipoietin encapsulated in multivesicular liposomes. Int J Pharm, 261:93-103. (Pubitemid 36962748)
11. Ramprasad MP, Anantharamaiah GM, Garber DW, Katre NV. (2002). Sustained-delivery of an apolipoprotein E-peptidomimetic using multivesicular liposomes lowers serum cholesterol levels. J Control Release, 79:207-218
12. Zhong H, Deng Y, Wang X, Yang B. (2005). Multivesicular liposome formulation for the sustained delivery of breviscapine. Int J Pharm, 301:15-24.
13. Van der Merwe SM, Verhoef JC, Verheijden JHM, Kotzé AF, Junginger HE. (2004). Trimethylated chitosan as polymeric absorption enhancer for improved peroral delivery of peptide drugs. Eur J Pharm Biopharm, 58:225-235
14. Thanou M, Verhoef JC, Verheijden JHM, Junginger HE. (2001). Intestinal absorption of octreotide using trimethyl chitosan chloride: Studies in pigs. Pharm Res, 18:823-828
15. Sieval AB, Thanou M, Kotzé AF, Verhoef JC, Brussee J, Junginger HE. (1998). Preparation and NMR characterization of highly substituted N-trimethyl chitosan chloride. Carbohyd Polym, 36:157-165
16. Hamman JH, Kotze AF. (2001). Effect of the type of base and number of reaction steps on the degree of quaternization and molecular weight of N-trimethyl chitosan chloride. Drug Dev Ind Pharm, 27:373-380
17. Kim S, Turker MS, Chi EY, Sela S, Martin GM. (1983). Preparation of multivesicular liposomes. Biochim Biophys Acta, 728:339-348
18. Du S, Deng YJ. (2006). Studies on the encapsulation of oxymatrine into liposomes by ethanol injection and pH gradient method. Drug Dev Ind Pharm, 32:791-797
19. Polnok A, Borchard G, Berhoef JC, Sarisuta N, Junginger HE. (2004). Influence of methylation process on the degree of quaternization of N-trimethyl chitosan chloride. Eur J Pharm Biopharm, 57:77-83.
20. Thanou M, Verhoef JC, Marbach P, Junginger HE. (2000). Intestinal absorption of octreotide: N-trimethyl chitosan chloride (TMC) ameliorates the permeability and absorption properties of the somatostatin analogue in vitro and in vivo. J Pharm Sci, 89:951-957
21. Thanou M, Verhoef JC, Junginger HE. (2001). Chitosan and its derivatives as intestinal absorption enhancers. Adv Drug Deliv Rev, 50:S91-101. (Pubitemid 32905357)
22. Zheng QZ, Liu LJ, Bai XC. (2007). Preparation of oxymatrine liposomes and evaluation of the quality. China Pharm, 18:760-762
23. Gregoriadis G. (1993). Liposome techology. 2nd ed. London: CRC.
24. Wang ML, Zhou QL, Wang BX. (2001). Studies on metabolism of oxymatrine by human intestinal bacteria. China J Chin Mater Med, 26:272.